tanshinone has been researched along with Dyskinesia Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, WY; Li, ZH; Liu, XY; Luo, ZJ; Sun, SK; Tang, J; Zhang, H; Zhang, T; Zhu, C | 1 |
| Feng, J; Yan, J; Yang, X | 1 |
2 other study(ies) available for tanshinone and Dyskinesia Syndromes
| Article | Year |
|---|---|
Inhibition of the spinal astrocytic JNK/MCP-1 pathway activation correlates with the analgesic effects of tanshinone IIA sulfonate in neuropathic pain.
Topics: Abietanes; Analgesics; Analysis of Variance; Animals; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Male; MAP Kinase Signaling System; Movement Disorders; Neuralgia; Pain Threshold; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Nerves | 2015 |
Treatment with tanshinone IIA suppresses disruption of the blood-brain barrier and reduces expression of adhesion molecules and chemokines in experimental autoimmune encephalomyelitis.
Topics: Abietanes; Animals; Blood-Brain Barrier; Calcium-Binding Proteins; Cell Adhesion Molecules; Chemokines; Demyelinating Diseases; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Glial Fibrillary Acidic Protein; Microfilament Proteins; Movement Disorders; Rats; Rats, Inbred Lew; Tight Junction Proteins | 2016 |